One of my favorite parts of this story is the Insmed CEO who says the "goal of the company is to make medicine available to those patients who can benefit from it," right after the story notes the company isn't launching its new lung disease drug in Europe and the UK citing concerns around MFN.
In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
